Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. 2006

Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
The Department of Cardiology, The Canberra Hospital, Canberra, Australia.

BACKGROUND There is limited information regarding the clinical utility of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) for the detection of left ventricular (LV) dysfunction in the community. We evaluated predictors of circulating NT-proBNP levels and determined the utility of NT-proBNP to detect systolic and diastolic LV dysfunction in older adults. METHODS A population-based sample of 1229 older adults (mean age 69.4 years, 50.1% women) underwent echocardiographic assessment of cardiac structure and function and measurement of circulating NT-proBNP levels. RESULTS Predictors of NT-proBNP included age, female sex, body mass index, and cardiorenal parameters (diastolic dysfunction [DD] severity; LV mass and left atrial volume; right ventricular overload; decreasing ejection fraction [EF] and creatinine clearance). The performance of NT-proBNP to detect any degree of LV dysfunction, including mild DD, was poor (area under the curve 0.56-0.66). In contrast, the performance of NT-proBNP for the detection of EF < or = 40% and moderate-severe DD was strong with area under the curve of > 0.90 regardless of age and sex; history of hypertension, diabetes, coronary artery disease; or body mass category. The ability of NT-proBNP to detect EF < or = 40% and/or moderate-severe DD was optimized by using age/sex-specific limits. Of "false-positive" tests, 88% (124/141) were explained after considering cardiorenal determinants of NT-proBNP levels. CONCLUSIONS Amino-terminal pro-B-type natriuretic peptide is a suboptimal marker of mild LV dysfunction, but performs strongly as a marker of EF < or = 40% and/or moderate-severe DD in the community. Most subjects with a positive NT-proBNP test, using age/sex-specific cutoffs, had prognostically significant abnormalities of cardiac structure or function.

UI MeSH Term Description Entries
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D003971 Diastole Post-systolic relaxation of the HEART, especially the HEART VENTRICLES. Diastoles
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013599 Systole Period of contraction of the HEART, especially of the HEART VENTRICLES. Systolic Time Interval,Interval, Systolic Time,Intervals, Systolic Time,Systoles,Systolic Time Intervals,Time Interval, Systolic,Time Intervals, Systolic
D018487 Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall. LV Diastolic Dysfunction,LV Dysfunction,LV Systolic Dysfunction,Left Ventricular Diastolic Dysfunction,Left Ventricular Dysfunction,Left Ventricular Systolic Dysfunction,Diastolic Dysfunction, LV,Dysfunction, LV,Dysfunction, LV Diastolic,Dysfunction, LV Systolic,Dysfunction, Left Ventricular,LV Diastolic Dysfunctions,LV Dysfunctions,LV Systolic Dysfunctions,Left Ventricular Dysfunctions,Systolic Dysfunction, LV
D020097 Natriuretic Peptide, Brain A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. Brain Natriuretic Peptide,Nesiritide,B-Type Natriuretic Peptide,BNP Gene Product,BNP-32,Brain Natriuretic Peptide-32,Natrecor,Natriuretic Factor-32,Natriuretic Peptide Type-B,Type-B Natriuretic Peptide,Ventricular Natriuretic Peptide, B-type,BNP 32,Brain Natriuretic Peptide 32,Natriuretic Factor 32,Natriuretic Peptide Type B,Natriuretic Peptide, B-Type,Natriuretic Peptide, Type-B,Natriuretic Peptide-32, Brain,Peptide, Brain Natriuretic,Peptide-32, Brain Natriuretic,Type B Natriuretic Peptide,Ventricular Natriuretic Peptide, B type

Related Publications

Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
January 2006, Journal of the American College of Cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
July 2014, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
February 2008, The American journal of cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
June 2006, Clinical biochemistry,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
October 2011, Journal of the American College of Cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
February 2008, The American journal of cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
January 2012, Congenital heart disease,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
February 2008, The American journal of cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
August 2009, Pediatric cardiology,
Walter P Abhayaratna, and Thomas H Marwick, and Niels G Becker, and Ian M Jeffery, and Darryl A McGill, and Wayne T Smith
November 2014, Journal of hypertension,
Copied contents to your clipboard!